Direct compression of 3-cyanopyridine as a pharma-grade solid dosage form is constrained less by compression force than by local heat accumulation at the punch tip. Commercial pharmaceutical use of 3-cyanopyridine as a finished API is rare; the substance is more often converted to nicotinamide or nicotinic acid, so direct dosage-form development must be supported by in-house data rather than compendial monographs. The substance has a melting range of 50–52 °C and is sold as a low-melting crystalline powder; without cooling, a rotary tablet press operating at turret speeds above 25–35 rpm can raise die wall temperature above 40 °C, which is too close to the melting onset for reliable tablet formation. Published data for 3-cyanopyridine direct compression is limited; therefore, the following machine setup is derived from pharmaceutical production of low-melting actives rather than from a compendial monograph. A Korsch XL 400 or Fette 2200i with cooled punches and a chilled die table at 5–10 °C should be evaluated. Pre-blending in a V-blender at ≤15 rpm for 12–15 min with microcrystalline cellulose (Ph. Eur. 101), anhydrous dibasic calcium phosphate (USP), and sodium stearyl fumarate (Ph. Eur.) at 0.5–1.5 % w/w is the starting formulation. If ambient humidity exceeds 60 % RH, pre-drying of the API in a vacuum dryer at 35 °C is required. The blend must be tested for bulk and tapped density according to USP <616> and for flow through an orifice using USP <1174>; a Hausner ratio between 1.12 and 1.35 and a Carr index between 10 % and 25 % are typical acceptance ranges for direct compression blends. A flow function coefficient below 4 is unacceptable for direct compression. The compressibility of the drug substance itself has not been published, and pre-compression force must be limited to avoid localized melting. In-process tablet hardness should be maintained between 40–80 N, friability below 1.0 % per USP <1216>, and disintegration time below 15 min in water at 37 °C per USP <701>. The pyridine nitrogen is weakly basic and largely unionized at gastric pH, so dissolution media may require 0.1 % w/v sodium lauryl sulfate to achieve sink conditions and avoid a false dissolution failure under USP <711>. Because of the low melting point, the formulation should not be compressed on a high-speed press without a thermal mapping study, and process validation must include thermocouple probes placed no more than 3 mm from the die bore inner surface.

Why Do Hard Capsule Fillers Require a Narrow Tamping-Pin Depth for Nitrile APIs?

Hard gelatin capsule filling of 3-cyanopyridine illustrates the conflict between powder flow and thermal sensitivity. The API's melting range of 50–52 °C is lower than the glass transition temperature of gelatin, so the heat of mechanical compaction inside a dosator or tamping pin can produce local fusion. On a Bosch GKF 2500 or Harro Höfliger KFM-3, tamping-pin depths above 0.3–0.5 mm have been observed to create glossy, compacted plugs for low-melting actives; published data for 3-cyanopyridine capsules are limited. The fill formulation should contain 0.5–1.0 % w/w colloidal silicon dioxide (Ph. Eur.) to improve flow, but excessive glidant raises the risk of delayed dissolution. Pre-drying at 30 °C and 35 % RH is required because equilibrium moisture above 1.5 % w/w in the blend may accelerate nitrile hydrolysis. Hard gelatin capsule shells are supplied with a shell moisture content of 13–16 % w/w; a conditioning step at 25 °C / 35 % RH for 24–48 h prevents moisture transfer. Fill weight uniformity is tested per USP <905>; dissolution is tested in 0.1 N HCl plus 0.1 % w/v sodium lauryl sulfate using USP <711> apparatus II at 50 rpm. Because the pyridine ring is not fully protonated at gastric pH, sink conditions may not be achieved without surfactant; this is a formulation requirement, not a compendial exception. In semi-automatic capsule fillers, the operator must monitor blend bed temperature continuously with an infrared sensor; if the bed temperature exceeds 35 °C, the run should be stopped and the blend cooled before restarting. Capsule shells made from HPMC are preferred when alkaline hydrolysis of the nitrile group is a concern, because they contain no gelatin and typically transfer less moisture; however, published data for 3-cyanopyridine in HPMC capsules are not available.

Because the nitrile substituent of 3-cyanopyridine is hydrolyzed under both acidic and alkaline conditions, aqueous high-shear granulation must be designed around a narrow water budget. In a GEA Aeromatic-Fielder or equivalent high-shear mixer, the dry powder bed is wetted with a binder solution containing 2–4 % w/w hypromellose (Ph. Eur. 2910) in purified water, but the granulation liquid must be buffered to pH 5.0–5.5 with 10 mM citrate buffer; this pH range represents the least hydrolytic burden for simple aromatic nitriles. Published data for 3-cyanopyridine wet granulation are limited, and the rate of hydrolysis under granulation conditions must be measured in a forced-degradation study per ICH Q1A(R2). The granulation end point is best determined by impeller torque rather than by visual consistency; torque increase above 2–3 N·m beyond the dry powder baseline indicates that water has been excessively localized. Drying in a fluid-bed dryer with inlet air at 45–50 °C and product temperature not exceeding 40 °C prevents melting and minimizes nitrile degradation. Loss on drying is controlled to 1.0 % w/w maximum using Ph. Eur. 2.2.32 or USP <731>. The dried granules are comminuted through a 1.0 mm conical mill; the granule fraction between 250 µm and 850 µm is retained for compression. If the granulation runs hotter than 42 °C, the substance may soften and fuse to the filter bags, causing batch-to-batch yield loss; this failure has been observed for low-melting actives with melting onset below 60 °C, although not specifically published for 3-cyanopyridine. Magnesium oxide and sodium carbonate must be excluded from the formulation because their alkaline microenvironments accelerate nitrile hydrolysis; stearic acid is preferred over magnesium stearate as a lubricant because magnesium salts can produce localized alkaline conditions. Tablets produced from wet granulation should be tested for organic impurities using a stability-indicating HPLC method, with the nicotinic acid impurity controlled to ≤0.10 % w/w, nicotinamide controlled to ≤0.15 % w/w, and unspecified impurities controlled to ≤0.10 % w/w per ICH Q3B(R2). Published data for this specific configuration is limited, so these limits are proposed starting specifications rather than compendial requirements.

Injectable Solution pH Boundaries and Terminal Sterilisation Failure Modes

An injectable presentation of 3-cyanopyridine must be compounded with the understanding that the substance is not a simple salt but a neutral low-melting solid with limited buffered solubility. If the drug substance is dissolved in Water for Injection, the pH must be adjusted to 4.5–5.5 with 10 mM citrate or acetate buffer; at pH 7.4, the nitrile group is progressively hydrolyzed to nicotinamide and nicotinic acid, so phosphate-buffered saline is unsuitable. Published data for the solubility of 3-cyanopyridine in Water for Injection is limited; a preliminary solubility screen should be conducted at 25 °C and 37 °C over 0.1–50 mg/mL. Because the melting point is 50–52 °C, aseptic filtration is preferred over terminal steam sterilization; the filter membrane must be compatible with low-melting solutes and should not be exposed to temperatures above 40 °C during filter integrity testing. Terminal sterilization at 121 °C for 15 min delivers an F0 of 8 min but may produce degradation products above 0.1 %; published data for 3-cyanopyridine under saturated steam sterilization is limited. If aseptic processing is selected, the process must meet FDA 21 CFR 211.113 and EU GMP Annex 1 requirements for environmental monitoring. The solution should be filtered through a 0.22 µm sterilizing-grade PVDF filter; a double-filter configuration reduces the risk of nitrile adsorption to the membrane. Visible particulate matter is controlled by USP <788>, bacterial endotoxins by USP <85>, and sterility by USP <71>. The unbuffered solution may show pH drift during storage because the substance can hydrolyze; a stability study under ICH Q1A(R2) at 25 °C / 60 % RH and 40 °C / 75 % RH must include pH, assay, and related-substance monitoring at 0, 1, 2, 3, 6, 12, 18, 24, and 36 months. The use of vial types should be limited to borosilicate glass Type I per USP <660>; the stopper must be selected for low endotoxin and extractable profile. If the pH shifts above 6.0, the batch should be quarantined and sampled for nitrile hydrolysis products. The injection solution should not be terminally autoclaved in flexible PVC bags because the nitrile group may be adsorbed and the thermal load exceeds the safe stability window.

For a lyophilized injectable presentation, the critical formulation parameter is not the freeze-drying cycle but the glass transition temperature of the partially frozen solution. 3-Cyanopyridine is a small molecule that may crystallize or remain amorphous during freezing; published data on its behavior in mannitol or trehalose matrices is limited. A lyophilization formulation should include a crystalline bulking agent such as mannitol (Ph. Eur.) at 20–50 mg/mL and a stabilizing sugar such as trehalose dihydrate (Ph. Eur.) at 10–30 mg/mL. The solution is filled into 10 mL Type I borosilicate glass vials and loaded into a Lyostar II or equivalent freeze dryer. The primary drying shelf temperature must be set below the collapse temperature; because the collapse temperature of 3-cyanopyridine-containing formulations has not been published, a freeze-dry microscopy study is required before cycle development. A conservative starting cycle uses a freezing ramp of −1 °C/min to −45 °C, a primary drying shelf temperature of −20 °C for 4–8 h, and a secondary drying temperature of 25 °C for 6 h. The nitrile group may undergo hydrolysis in the presence of residual moisture; therefore, the final cake moisture must be controlled below 1.0 % w/w by Karl Fischer titration according to USP <921> Method Ia. Reconstitution with Water for Injection should yield a solution with pH 4.5–5.5; the reconstituted solution must be used immediately because the hydrolytic stability of the nitrile group in water is limited. The lyophilized cake should be a white to off-white solid; discoloration indicates thermal or oxidative degradation. The sealed vials should be stored at 2–8 °C unless long-term stability data at room temperature is available. Published data for this specific configuration is limited, and the freeze-dry cycle must be validated with thermocouple vials to ensure that the product temperature remains below the glass transition or collapse temperature throughout primary drying.

When Sachet Sealing Jaws Operate Above the API’s Melting Onset

Granules intended for single-dose sachets are not simply tablets ground to a smaller size; they must be engineered to flow, dose volumetrically, and survive sealing heat. For 3-cyanopyridine, a granule fraction with particle size between 300 µm and 710 µm is preferred for sachet filling. The granules are produced by low-temperature wet granulation or by dry granulation using a roll compactor with roll pressure of 10–20 bar; published data for 3-cyanopyridine in sachet formulations are limited. Dry granulation avoids water contact and is preferred when nitrile hydrolysis is the dominant stability risk. The granules should be filled into aluminum-laminated sachets with a polyethylene inner layer; the heat-sealing jaws operate at 130–180 °C, and the product must be protected from conductive heat. The filling line should include a cooled sealing station or a spacer to prevent granule temperature exceeding 35 °C. Granule flow through the sachet filler is measured by USP <1174>; a mass flow rate of ≤2 g/s is typical for small-dose sachets. The finished product must meet USP <905> for weight variation and a dissolution test per USP <711> using 0.1 N HCl with surfactant. The sachet packaging material must be tested for seal integrity per ASTM F1140 and for moisture vapor transmission. Because the API melts at 50–52 °C, any secondary thermal processing, such as hot-stamping of lot numbers, must be performed on the outer packaging only. In warm climates, sachets should be stored below 30 °C and protected from moisture; stickers and labels applied with hot-melt adhesives should not contact the product contact layer. Sodium stearyl fumarate at 0.5–1.0 % w/w is used as the intragranular lubricant to avoid the hydrolytic alkaline conditions associated with magnesium stearate. A confirmatory stability study under ICH Q1A(R2) at 30 °C / 65 % RH and 40 °C / 75 % RH should include appearance, nitrile assay, nicotinic acid, nicotinamide, moisture, and dissolution.